Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz)
Klinisch orientierter Schwerpunkt / Johannes Gutenberg-Universität Mainz
Kaufmann, Justus; Haist, Maximilian; Kur, Ivan et al.
Quantification of invasion patterns as a predictive factor for the therapeutic response of oropharyngeal squamous cell carcinoma to radiochemotherapySTRAHLENTHERAPIE UND ONKOLOGIE. Bd. 199. 2023 S. S35-S36
Thurner, Lorenz; Ziepert, Marita; Berdel, Christian et al.
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER StudyHEMASPHERE. Bd. 7. H. 7. 2023
Held, Gerhard; Thurner, Lorenz; Poeschel, Viola et al.
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER TrialHEMASPHERE. Bd. 7. H. 7. 2023
Oertel, Michael; Hering, Dominik; Nacke, Nina et al.
Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern EraADVANCES IN RADIATION ONCOLOGY. Bd. 8. H. 3. 2023
Schlenk, R. F.; Weber, D.; Krzykalla, J. et al.
Randomized phase-III study of low-dose cytarabine and etoposide? plus ?/- all-<i>trans</i> retinoic acid in older unfit patients with <i>NPM1</i>-mutated acute myeloid leukemiaSCIENTIFIC REPORTS. Bd. 13. H. 1. 2023
Nowakowski, Grzegorz S.; Yoon, Dok Hyun; Mondello, Patrizia et al.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphomaANNALS OF HEMATOLOGY. Bd. 102. H. 7. 2023 S. 1773-1787
Hess, Georg; Vucinic, Vladan; Rejeski, Kai et al.
Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss AnalysisBLOOD. Bd. 142. 2023
Decker, Thomas; Brucker, Cosima; Engel, Anne et al.
Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNAJOURNAL OF CLINICAL ONCOLOGY. Bd. 41. H. 16. 2023
Krajnak, Slavomir; Krajnakova, Jana; Anic, Katharina et al.
Real-world experience of metronomic chemotherapy in metastatic breast cancer: results of a retrospective unicenter studyBREAST CARE. 2023
Zahnreich, Sebastian; Yusifli, Kamran; Poplawski, Alicia et al.
Replication stress drives chromosomal instability in fibroblasts of childhood cancer survivors with second primary neoplasmsDNA REPAIR. Bd. 122. 2023